Technical Perspectives from CPhI Worldwide
PTSM: Pharmaceutical Technology Sourcing and Management
Pharmaceutical Technology's podcast series from CPhI.
Patricia Van Arnum, senior editor of Pharmaceutical Technology, discusses strategies in optimizing API syntheses and manufacturing. Participants include Jan-Olav Henck, PhD, chief scientific officer at Aptuit, Fred Fleitz, senior manager of process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories. Also, Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011 and other CPhI events.
Listen here to a podcast with Jan-Olav Henck, PhD, chief scientific officer at Aptuit, who discusses strategies and considerations in polymorph screening.
Listen here to a podcast with Fred Fleitz, senior manager, process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories, discuss recent project work in optimizing several API syntheses. Fleitz discusses the approach taken in a condensation reaction between a naphthoquinone derivative and a substituted methyl vinyl ketone. McDonald discusses the optimization of a synthetic route for a complex natural product analogue. In another project, he discusses an approach taken to maintain the desired enantioselectivity of a molecule containing a chiral cyclopropane moiety during scale-up.
Listen here to a podcast with Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011, and other CPhI events.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
